DOMAINEX LIMITED

1. Industry Classification

Domainex Limited is classified under SIC codes 72110 (research and experimental development on biotechnology) and 72190 (other research and experimental development on natural sciences and engineering). It operates as a UK-based contract research organisation (CRO) within the life sciences sector, providing preclinical drug discovery services—principally chemistry and biology solutions—to pharmaceutical, biotechnology, and academic clients worldwide.

Key sector characteristics include: - A talent-intensive, science-driven business model with high barriers to entry in specialised capabilities such as structural biology, biophysics, and computational chemistry. - Project-based revenue with potential for client concentration, particularly where a single large pharma or biotech account represents a material share of billings. - Strong geographic clustering, with the Cambridge cluster offering proximity to major pharma R&D sites, a deep scientific labour pool, and university-linked innovation. - A mix of commoditised routine chemistry (price-sensitive and exposed to offshore competition) and higher-value, IP-rich discovery work (capable of commanding premium pricing). - Dependence on client R&D budgets and biotech fundraising cycles, making demand sensitive to macroeconomic conditions and venture capital availability.

Based on its filed balance sheet and turnover (approximately £10.5m–£13.3m in recent years), Domainex sits in the mid-sized private company band—below the large full-service CROs but above the smallest boutique laboratories.

2. Relative Performance

Against typical UK preclinical CRO benchmarks, Domainex’s recent performance reflects a restructuring phase rather than steady expansion:

• Revenue: Turnover fell from a peak of £13.3m in 2023 to approximately £11.0m in 2024 and approximately £10.45m in 2025, a decline of roughly one-fifth over two years. The accounts attribute this principally to the loss of a major synthetic chemistry client.
• Profitability: The operating loss narrowed from £1.35m to £0.66m, and EBITDA moved to a positive £0.35m (an increase of £0.64m). The loss after tax was £565k in 2025 compared with £1.05m in 2024.
• Margins: Gross margin improved to 46.98% from 42.42%, suggesting a favourable shift in service mix or pricing despite lower volumes.
• Balance sheet: Net assets declined from £7.2m (2023) to £6.16m (2024) and £5.6m (2025). Cash balances fell sharply from £2.6m to £0.97m and then £0.46m, leaving a relatively thin liquidity cushion for a business of this scale.
• Liquidity and funding: The company is pursuing a £1.0m–£1.5m equity raise to fund restructuring and growth; the accounts state that applications for over £1m had been received from shareholders at the time of approval.

Relative to sector norms, a gross margin near 47% is credible for a mixed chemistry/biology CRO but below the higher margins often achieved by pure-play biologics or specialised modality providers. The revenue scale and net asset trajectory position Domainex as a niche participant rather than a market leader in the broader UK CRO landscape.

3. Sector Trends Impact

Several industry dynamics are directly shaping Domainex’s outlook:

• Biotech funding constraints: Macroeconomic and funding uncertainty for biotech clients continues to affect project timing and size, a principal risk noted in the strategic report. This affects demand across the UK CRO sector.
• Rising R&D outsourcing: Pharmaceutical and biotechnology sponsors continue to outsource discovery work to manage fixed costs, providing a structural tailwind for CROs with credible delivery track records.
• Commoditisation of routine chemistry: Lower-cost offshore providers exert pressure on standard synthetic chemistry services. Domainex’s loss of its major synthetic chemistry client exemplifies this pressure and underpins its strategic move away from commoditised work.
• Shift to biology-led and computational discovery: Industry demand is tilting toward integrated biology, computational chemistry, and AI-assisted workflows. Domainex’s pivot toward its Direct-to-Biology platform and computational infrastructure aligns with this trend.
• Site rationalisation: High property costs in the Cambridge corridor have prompted many life sciences firms to consolidate real estate. Domainex plans to close its Chesterford chemistry facility at lease expiry in November 2026 and operate from a single site, aiming to reduce fixed costs and management overhead.
• Financing environment: The need for an equity raise reflects the capital-intensive nature of restructuring and the tighter funding conditions affecting smaller life sciences service businesses.

4. Competitive Positioning

Domainex is best characterised as a niche, differentiated player within the UK preclinical CRO market rather than a global leader or broad-market follower.

Strengths versus typical competitors: - Proprietary and differentiated capabilities, including computational chemistry, structural biology, biophysics, and its Direct-to-Biology workflow, which create higher barriers to entry than routine chemistry services. - Cambridge location and scientific team, supporting client relationships and recruitment within a strong life sciences cluster. - Improved gross margin and reduced operating loss indicate that cost-control measures and service-mix shifts are taking effect. - A historically diverse client base across pharma, biotech, and academia, mitigating over-reliance on any single sector.

Weaknesses and competitive vulnerabilities: - Recent client concentration and the loss of a major chemistry account demonstrate vulnerability to large-client churn. - Dual-site operation (Chesterford and Unity Campus) has increased fixed-cost complexity; the planned closure introduces execution risk around client disruption, staff retention, and cost overruns. - A cash position of £0.46m at year-end 2025 is modest relative to operating needs, making the planned equity raise critical to near-term stability. - Smaller scale than large full-service CROs with global laboratory networks, limiting its ability to offer end-to-end development services without partnerships.

Overall, Domainex competes by avoiding price-based competition in commoditised chemistry and instead targeting higher-value, IP-rich discovery work where it can demonstrate scientific leadership and secure premium pricing. Its competitive position depends on successfully executing the Chesterford closure, retaining critical staff, winning new business in computational and biology-led services, and completing its equity financing.